Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR-2302
- Development stage
- Preclinical
- Lead developer
- Bliss Media
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BR-2302 is a preclinical-stage bispecific antibody-drug conjugate (ADC) developed by Bliss Biopharmaceutical (BlissBio). It is designed to simultaneously target the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor 3 (HER3), two members of the ErbB family frequently co-expressed in various solid tumors. The ADC utilizes a bispecific antibody backbone conjugated to an Exd-containing payload, which is a proprietary exatecan derivative that acts as a topoisomerase I inhibitor. By targeting both EGFR and HER3, BR-2302 aims to enhance tumor-specific delivery of the cytotoxic payload and overcome resistance mechanisms associated with monospecific therapies. The program is currently in preclinical development for the treatment of advanced solid tumors.
- Other names
- HER3×EGFR bispecific ADCEGFR/HER3 bispecific ADC
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TOP1 (DNA Topoisomerase I)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on BR-2302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR-2302.